Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Desmoplasia is a prominent feature of pancreatic ductal adenocarcinoma (PDA). Stromal desmoplasia reflects the low cellularity that is characteristic of PDA, and it may play a role in PDA chemoresistance. In this retrospective study, we evaluated the relationship between tumor cellularity in resected PDA specimens and long-term patient outcomes. Methods: We retrospectively reviewed the data from 175 patients who underwent PDA resection between January 2010 and December 2015 at Seoul National University Bundang Hospital, and analyzed their clinicopathological features and the relationship between tumor cellularity (high vs low based on a cutoff of 30% cellularity) and patient outcomes. Results: The high-cellularity group had significantly shorter overall survival (OS) (18.7 months vs 26.6 months, p=0.006) and disease-free survival (11.0 months vs 16.9 months, p=0.031) than the low-cellularity group. Multivariate analysis revealed that high tumor cellularity was an independent risk factor for poor OS (hazard ratio, 2.008; 95% confidence interval, 1.361 to 2.962; p<0.001). Adjuvant therapy improved OS in the low-cellularity group (16.3 months vs 41.3 months, p=0.001) but not in the high-cellularity group (15.9 months vs 24.4 months, p=0.107). Conclusions: Tumor cellularity in PDA specimens may be a prognostic and predictive biomarker that could aid in identifying patients who would benefit from adjuvant therapy for PDA.
Abstract
Background/Aims: Desmoplasia is a prominent feature of pancreatic ductal adenocarcinoma (PDA). Stromal desmoplasia reflects the low cellularity that is characteristic of PDA, and it may play a role in PDA chemoresistance. In this retrospective study, we evaluated the relationship between tumor cellularity in resected PDA specimens and long-term patient outcomes. Methods: We retrospectively reviewed the data from 175 patients who underwent PDA resection between January 2010 and December 2015 at Seoul National University Bundang Hospital, and analyzed their clinicopathological features and the relationship between tumor cellularity (high vs low based on a cutoff of 30% cellularity) and patient outcomes. Results: The high-cellularity group had significantly shorter overall survival (OS) (18.7 months vs 26.6 months, p=0.006) and disease-free survival (11.0 months vs 16.9 months, p=0.031) than the low-cellularity group. Multivariate analysis revealed that high tumor cellularity was an independent risk factor for poor OS (hazard ratio, 2.008; 95% confidence interval, 1.361 to 2.962; p<0.001). Adjuvant therapy improved OS in the low-cellularity group (16.3 months vs 41.3 months, p=0.001) but not in the high-cellularity group (15.9 months vs 24.4 months, p=0.107). Conclusions: Tumor cellularity in PDA specimens may be a prognostic and predictive biomarker that could aid in identifying patients who would benefit from adjuvant therapy for PDA.
참고문헌 (31)
- Hidalgo M, "Pancreatic cancer", N Engl J Med, 362, pp.1605~1617 (2010)
- Siegel RL, "Cancer statistics, 2016", CA Cancer J Clin, 66, pp.7~30 (2016)
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Von Hoff DD, "Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer : a phase I", II trial, 2011, pp.29, 4548~4554
- Malvezzi M, "European cancer mortality predictions for the year 2016 with focus on leukaemias", Ann Oncol, 27, pp.725~731 (2016)
- Vincent A, "Pancreatic cancer", Lancet, 378, pp.607~620 (2011)
- Cameron JL, "One thousand consecutive pancreaticoduodenectomies", Ann Surg, 244, pp.10~15 (2006)
- Kayahara M, "An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging", Cancer, 72, pp.2118~2123 (1993)
- Sohn TA, "Resected adenocarcinoma of the pancreas-616 patients : results, outcomes, and prognostic indicators", J Gastrointest Surg, 4, pp.567~579 (2000)
- Staley CA, "Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head", Am J Surg, 171, pp.118~124 (1996)
- Trede M, "Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality", Ann Surg, 211, pp.447~458 (1990)
- Mahadevan D, "Tumor-stroma interactions in pancreatic ductal adenocarcinoma", Mol Cancer Ther, 6, pp.1186~1197 (2007)
- Biankin AV, "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes", Nature, 491, pp.399~405 (2012)
- Neesse A, "Stromal biology and therapy in pancreatic cancer", Gut, 60, pp.861~868 (2011)
- Jacobetz MA, "Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer", Gut, 62, pp.112~120 (2013)
- Michl P, "Improving drug delivery to pancreatic cancer : breaching the stromal fortress by targeting hyaluronic acid", Gut, 61, pp.1377~1379 (2012)
- Olive KP, "Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer", Science, 324, pp.1457~1461 (2009)
- Hingorani SR, "High response rate and PFS with PEGPH20 added to nab-paclitaxel", gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors : interim results of a randomized phase II study, 2015, pp.33(15 Suppl), 4006~
- Martín J, "Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors : a study by the Spanish Group for Sarcoma Research(GEIS)", J Clin Oncol, 23, pp.6190~6198 (2005)
- Bloom HJ, "Histological grading and prognosis in breast cancer : a study of 1409 cases of which 359 have been followed for 15 years", Br J Cancer, 11, pp.359~377 (1957)
- Sener SF, "Pancreatic cancer : a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database", J Am Coll Surg, 189, pp.1~7 (1999)
- Lunardi S, "The stromal compartments in pancreatic cancer : are there any therapeutic targets", Cancer Lett, 343, pp.147~155 (2014)
- Heid I, "Co-clinical assessment of tumor cellularity in pancreatic cancer", Clin Cancer Res, 23, pp.1461~1470 (2017)
- Junttila MR, "Influence of tumour micro-environment heterogeneity on therapeutic response", Nature, 501, pp.346~354 (2013)
- Bijlsma MF, "The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials : a systematic review and critical appraisal", Cancer Metastasis Rev, 34, pp.97~114 (2015)
- Erkan M, "The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma", Clin Gastroenterol Hepatol, 6, pp.1155~1161 (2008)
- Park H, "The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma", Tumour Biol, 39, pp.1010428317718403~ (2017)
- Nielsen MF, "Key players in pancreatic cancer-stroma interaction : cancer-associated fibroblasts, endothelial and inflammatory cells", World J Gastroenterol, 22, pp.2678~2700 (2016)
- Özdemir BC, "Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival", Cancer Cell, 25, pp.719~734 (2014)
- Rhim AD, "Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma", Cancer Cell, 25, pp.735~747 (2014)
- Hwang RF, "Cancer-associated stromal fibroblasts promote pancreatic tumor progression", Cancer Res, 68, pp.918~926 (2008)